Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer.

Despite the recent consensus on the eligibility of adjuvant systemic therapy in patients with lymph node-negative breast cancer (NNBC) based on clinicopathologic criteria, specific biological markers are needed to predict sensitivity to the different available therapeutic options. We examined the feasibility of developing a genomic predictor of chemotherapy response and recurrence risk in 185 patients with NNBC using assembled arrays containing 2,460 bacterial artificial chromosome clones for scanning the genome for DNA copy number changes. After surgery, 90 patients received anthracycline-based chemotherapy, whereas 95 did not. Tamoxifen was administered to patients with hormone receptor-positive tumors. The association of genomic and clinicopathologic data and outcome was computed using Cox proportional hazard models and multiple testing adjustment procedures. Analysis of NNBC genomes revealed a common genomic signature. Specific DNA copy number aberrations were associated with hormonal receptor status, but not with other clinicopathologic variables. In patients treated with chemotherapy, none of the genomic changes were significantly correlated with recurrence. In patients not receiving chemotherapy, deletion of eight bacterial artificial chromosome clones clustered to chromosome 11q was independently associated with relapse (disease-free survival at 10 years+/-SE, 40%+/-14% versus 86%+/-6%; P<0.0001). The 54 patients with deletion of 11q (29%) did not present more aggressive clinicopathologic features than those without 11q loss. The adverse influence of 11q deletion on clinical outcome was confirmed in an independent validation series of 88 patients with NNBC. Our data suggests that patients with NNBC with the 11q deletion might benefit from anthracycline-based chemotherapy despite other clinical, pathologic, or genetic features. However, these initial findings should be evaluated in randomized clinical trials.

[1]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[2]  Harold C. Sox,et al.  National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐making , 1988 .

[3]  C. Croce,et al.  Suppression of tumorigenicity of breast cancer cells by microcell-mediated chromosome transfer: studies on chromosomes 6 and 11. , 1994, Cancer research.

[4]  G. Hampton,et al.  Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. , 1994, Cancer research.

[5]  C. Croce,et al.  Loss of heterozygosity at 11q22-q23 in breast cancer. , 1994, Cancer research.

[6]  G. Hampton,et al.  Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. , 1995, Cancer research.

[7]  J. Foekens,et al.  TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients , 1996, Genes, chromosomes & cancer.

[8]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[9]  R. Siebert,et al.  Detection of deletions in the short arm of chromosome 3 in uncultured renal cell carcinomas by interphase cytogenetics. , 1998, The Journal of urology.

[10]  Y Taya,et al.  Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.

[11]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[12]  M. James,et al.  11q23.1 and 11q25-qter YACs suppress tumour growth in vivo , 1999, Oncogene.

[13]  W. Cook,et al.  Accommodating haploinsufficient tumour suppressor genes in Knudson's model , 2000, Oncogene.

[14]  W. Kuo,et al.  Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene , 2000, Nature Genetics.

[15]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[16]  Daniel A Starr,et al.  Human Zw10 and ROD are mitotic checkpoint proteins that bind to kinetochores , 2000, Nature Cell Biology.

[17]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[18]  M Markman,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[19]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[20]  Ajay N. Jain,et al.  Assembly of microarrays for genome-wide measurement of DNA copy number , 2001, Nature Genetics.

[21]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[22]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  F. Kokocinski,et al.  Automated Screening for Genomic Imbalances using Matrix-Based Comparative Genomic Hybridization , 2002, Laboratory Investigation.

[24]  J. Martinez-Climent,et al.  Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Lahti-Domenici,et al.  Analysis of 11q21–24 loss of heterozygosity candidate target genes in breast cancer: Indications of TSLC1 promoter hypermethylation , 2002, Genes, chromosomes & cancer.

[26]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[27]  C. Croce,et al.  The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[29]  J. Bartek,et al.  Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. , 2003, Cancer cell.

[30]  T. Ried,et al.  H2AX Haploinsufficiency Modifies Genomic Stability and Tumor Susceptibility , 2003, Cell.

[31]  R. Gelber,et al.  Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[33]  D. Pinkel,et al.  Genomic Alterations in Primary Gastric Adenocarcinomas Correlate with Clinicopathological Characteristics and Survival , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[34]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[35]  Barbara J. Trask,et al.  Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes , 2004, Cancer Research.

[36]  Jane Fridlyand,et al.  Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors , 2004 .

[37]  J. Bryant,et al.  Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials , 2004, The Lancet.

[38]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[39]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  W. Lam,et al.  Comprehensive copy number profiles of breast cancer cell model genomes , 2006, Breast Cancer Research.

[41]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[42]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[43]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[44]  Carlos Caldas,et al.  Identification and validation of prognostic markers in breast cancer with the complementary use of array‐CGH and tissue microarrays , 2005, The Journal of pathology.

[45]  Markus Schilhabel,et al.  Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. , 2005, Blood.

[46]  D. Pinkel,et al.  Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. , 2005, Blood.

[47]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[48]  J. Bartek,et al.  Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA Breakage , 2005, Molecular and Cellular Biology.

[49]  P. Lichter,et al.  Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. , 2005, Cancer research.

[50]  J. Ausió,et al.  The anthracycline antibiotics: antitumor drugs that alter chromatin structure , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[51]  Joel Greshock,et al.  High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization , 2005, Breast Cancer Research.

[52]  Janet Hall.  The Ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants. , 2005, Cancer letters.

[53]  Jun Yao,et al.  Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. , 2006, Cancer research.

[54]  Ajay N. Jain,et al.  Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.

[55]  Juan F. García,et al.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.

[56]  J. Stockman,et al.  Distinct Sets of Genetic Alterations in Melanoma , 2007 .